Clinical trials: Refractory or Relapsed Multiple Myeloma
Multiple Myeloma, Solid Tumors
A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors
The purpose of this trial is to characterize the safety and toxicity of DKN-01 by determining a maximum-tolerated dose and associated dose limiting toxicity. To evaluate the pharmacodynamic response in patients with cancer.
- Conditions
- Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
- Trial name
- NCT01457417
- Testing
- DKN-01
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Leap Therapeutics, Inc.
Multiple Myeloma
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
One purpose of this study is to evaluate the effectiveness and safety in long term treatment for patients who completed preceding phase I/II study.
- Trial name
- NCT00216697
- Testing
- bortezomib
- Volunteers
- 13 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Multiple myeloma (MM) is an incurable malignancy and accounts for 1 percentage (%) of all cancers and for 10% of all hematologic malignancies.
- Trial name
- NCT03525678
- Testing
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 221 people
- Sponsor
- GlaxoSmithKline
Relapsed/Refractory Multiple Myeloma
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
The primary purpose of the phase 1 part of the study is to evaluate safety and tolerability of AMG 701 monotherapy to identify the RP2D for AMG 701 monotherapy followed by a dose-confirmation part to gather further safety data…
- Trial name
- NCT03287908
- Testing
- AMG 701, Pomalidomide, Dexamethasone
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Relapsed or Refractory Multiple Myeloma
A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma
The main purpose of this Phase I study is to access the safety and tolerability of Y150 at different dose levels. It is hoped to find out the recommended dose for Phase II/III.
- Trial name
- NCT05011097
- Testing
- Y150
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Refractory, Multiple Myeloma
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to assess the safety/tolerability and determine the Japanese recommended dose (RD) of bortezomib administered as a once-daily intravenous bolus twice weekly for 2 consecutive weeks(Days 1, 4, 8, and…
- Conditions
- Refractory, Multiple Myeloma, Relapse
- Trial name
- NCT00752518
- Testing
- bortezomib
- Volunteers
- 35 people
- Sponsor
- Janssen Pharmaceutical K.K.
Multiple Myeloma
Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma
This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.
- Trial name
- NCT00375791
- Testing
- perifosine, dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- AEterna Zentaris
Multiple Myeloma
Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Multiple myeloma (MM) accounts for more than 10% of all blood cancers and 1% of all cancers. The purpose of this study is to assess how safe lemzoparlimab is and how lemzoparlimab moves through the body of adult participants with…
- Trial name
- NCT04895410
- Testing
- Lemzoparlimab, Dexamethasone, Carfilzomib
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 8 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy, dose-escalation and dose expansion study. Forimtamig will be administered to participants with r/r MM for whom no standard-of-care treatment exists or…
- Trial name
- NCT04557150
- Testing
- Forimtamig
- Where
- 20 sites in Australia, Belgium and 7 more
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
Relapsed and/or Refractory Multiple Myeloma
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of ixazomib plus lenalidomide and dexamethasone in Japanese participants with relapsed and/or refractory multiple myeloma (RRMM).
- Trial name
- NCT02917941
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 21 sites in Japan
- Volunteers
- 34 people
- Sponsor
- Takeda
Multiple Myeloma
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- CERVINO (NCT06158841)
- Testing
- Etentamig, Carfilzomib, Pomalidomide
- Where
- 166 sites in United States, Australia and 23 more
- Volunteers
- 421 people
- Sponsor
- AbbVie
Multiple Myeloma
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01199718
- Testing
- CX-4945
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cylene Pharmaceuticals
Multiple Myeloma
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
- Trial name
- NCT00243763
- Testing
- TKI258
- Where
- 5 sites in United States
- Volunteers
- 64 people
- Sponsor
- Novartis
Multiple Myeloma
Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
This is a Phase 1b open-label study of ciforadenant, an oral, small molecule inhibitor targeting adenosine-2A receptors (A2AR), on safety/tolerability and efficacy in combination with daratumumab, a monoclonal antibody targeting…
- Trial name
- NCT04280328
- Testing
- Ciforadenant, daratumumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Multiple Myeloma
A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
The purpose of this study is to evaluate the percentage of participants with a response of very good partial response (VGPR) or better to IDd treatment.
- Trial name
- NCT03439293
- Testing
- Ixazomib, Daratumumab, Dexamethasone
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 61 people
- Sponsor
- Takeda
Multiple Myeloma
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT06223516
- Testing
- Subcutaneous (SC) Etentamig, Intravenous (IV) Etentamig
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 60 people
- Sponsor
- AbbVie
Relapsed/Refractory Multiple Myeloma
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
The purpose of this study is to evaluate the effects of the addition of SG301 injection to pomalidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT06508983
- Testing
- SG301 Injection, pomalidomide, dexamethasone
- Where
- 12 sites in China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Advanced Solid Tumors, Multiple Myeloma
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
For cancer cells to grow, they need to have nutrients supplied to them through blood vessels. The study drug, ACE-041, is designed to work by blocking the growth of those blood vessels and preventing cancer cells from growing.
- Trial name
- NCT00996957
- Testing
- ACE-041
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Relapsed and/or Refractory Multiple Myeloma
A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone
The purpose of this study is to investigate the real world effectiveness and safety of ixazomib in combination with lenalidomide and dexamethasone (IRd) in patients with relapsed and/or refractory multiple myeloma (RRMM), under…
- Trial name
- NCT03433001
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- Japan
- Volunteers
- 295 people
- Sponsor
- Takeda
Multiple Myeloma
A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
H9S-MC-JDCF was a multicenter non-randomized, single-arm, open-label, dose-escalation, dose confirmation, Phase 1 study of intravenous (IV) LY2127399 in combination with bortezomib in patients with refractory or relapsed MM.
- Trial name
- NCT00689507
- Testing
- LY2127399
- Where
- 6 sites in United States
- Volunteers
- 48 people
- Sponsor
- Applied Molecular Evolution